Scilex Holding (SCLX) Non Operating Investment Income (2025)
Scilex Holding (SCLX) recorded quarterly Non Operating Investment Income of -$5.6 million in Q4 2025, down 167.5% quarter-over-quarter from $8.3 million in Q3 2025.
Scilex Holding (SCLX) Non Operating Investment Income (2025) Analysis & Trends
Scilex Holding's Non Operating Investment Income history runs 1 years deep, the most recent figure standing at -$5.6 million for Q4 2025.
- In Q4 2025, Non Operating Investment Income changed N/A year-over-year to -$5.6 million; the TTM figure through Dec 2025 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was $2.7 million, changed N/A from the prior year.
- Non Operating Investment Income was -$5.6 million for Q4 2025 at Scilex Holding, down from $8.3 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $8.3 million in Q3 2025 to a low of -$5.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | - |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | - |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | - |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | - |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.59 Mn |
| Dec 31, 2025 | -5.59 Mn |
| Sep 30, 2025 | 8.28 Mn |
| Sep 30, 2025 | 8.28 Mn |